98%
921
2 minutes
20
Ethnopharmacology Relevance: Breast cancer is a prevalent disease among women, necessitating the discovery of new anti-tumor compounds. Falcaria vulgaris has traditional medicinal uses in Iran for treating ailments such as skin ulcers and gastrointestinal disorders.
Aim Of The Study: Given the cytotoxic effects of related plants, F. vulgaris may have potential for cancer treatment.
Materials And Methods: The F. vulgaris extracts were prepared using a Soxhlet apparatus and tested on MCF-7 breast cancer cells. The most potent extract was tested using 24 female BALB/c mice that had been injected with the 4T1 breast cancer cell line. Mice were divided into four groups: two received low (10 mg/kg) and high (20 mg/kg) doses of the extract, and the other groups served as controls. The tumor dimensions were measured, and tissues were analyzed for gene expression via real-time PCR. GC-MS analyzed the dichloromethane (DCM) extract to identify cytotoxic compounds.
Results: The in vitro study demonstrated that the DCM extract exhibited significant activity compared to other extracts and the control (P < 0.001). The high dose of the DCM extract significantly inhibited tumor growth, reduced tumor volume in mice. This effect was linked to changes in the expression of cancer-related genes (caspase 3 and 9), as well as inhibition of cell proliferation and induction of cell death.
Conclusion: F. vulgaris demonstrated anticancer effects and can be considered a valuable plant for treating cancer in the future.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jep.2025.120336 | DOI Listing |
JAMA Netw Open
September 2025
Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Importance: Patients with advanced cancer frequently receive broad-spectrum antibiotics, but changing use patterns across the end-of-life trajectory remain poorly understood.
Objective: To describe the patterns of broad-spectrum antibiotic use across defined end-of-life intervals in patients with advanced cancer.
Design, Setting, And Participants: This nationwide, population-based, retrospective cohort study used data from the South Korean National Health Insurance Service database to examine broad-spectrum antibiotic use among patients with advanced cancer who died between July 1, 2002, and December 31, 2021.
Obstet Gynecol
July 2025
Graduate School of Medicine, University of Wollongong, Wollongong, New South Wales, Australia.
Med Oncol
September 2025
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Neuropeptide Y (NPY) and the voltage-gated potassium channel Kv1.3 are closely associated with breast cancer progression and apoptosis regulation, respectively. NPY receptors (NPYRs), which are overexpressed in breast tumors, contribute to tumor growth, migration, and angiogenesis.
View Article and Find Full Text PDFIn Vitro Cell Dev Biol Anim
September 2025
Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama-shi, Okayama, 700-8558, Japan.
S100 protein family members S100A8 and S100A9 function primarily as a heterodimer complex (S100A8/A9) in vivo. This complex has been implicated in various cancers, including gastric cancer (GC). Recent studies suggest that these proteins play significant roles in tumor progression, inflammation, and metastasis.
View Article and Find Full Text PDFJ Neurooncol
September 2025
Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
Purpose: Breast cancer (BC) is the most frequent cancer among women and the second leading cause of central nervous system (CNS) metastases. While the epidemiology of CNS metastases from BC has been well described, little is known about the treatment patterns and outcomes of young women < 40 years of age with BC that is metastatic to the CNS.
Methods: In this retrospective analysis, we identified patients with metastatic breast cancer (MBC) to the CNS who were treated at the Sunnybrook Odette Cancer Center, Toronto, Canada between 2008 and 2018.